TTNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TTNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Titan Pharmaceuticals's PE Ratio without NRI is 0.00. Titan Pharmaceuticals's 5-Year EBITDA growth rate is 58.20%. Therefore, Titan Pharmaceuticals's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Titan Pharmaceuticals's PEG Ratio or its related term are showing as below:
During the past 13 years, Titan Pharmaceuticals's highest PEG Ratio was 3.59. The lowest was 0.19. And the median was 0.77.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Titan Pharmaceuticals's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Titan Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Titan Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Titan Pharmaceuticals's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Titan Pharmaceuticals's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 58.20 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Titan Pharmaceuticals (NAS:TTNP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Titan Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Seow Gim Shen | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
Sire Group Ltd. | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
David Natan | director | 11190 BISCAYNE BLVD, MIAMI FL 33181 |
Matthew Charles Mcmurdo | director | 1047 SEWARD AVE., WESTFIELD NJ 07090 |
Peter Louis Chasey | director | 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129 |
Eric Howard Greenberg | director | 710 CARLYLE ST, WOODMERE NY 11598 |
Avraham Ben-tzvi | director | 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544 |
Katherine Beebe | director, officer: President and COO | 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
Choon Hau Choong | 10 percent owner | NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060 |
David E. Lazar | director, 10 percent owner, officer: Chief Executive Officer | VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000 |
Activist Investing Llc | other: Member of 10% owner group | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036 |
Joseph A Akers | director | 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111 |
James R Mcnab | director | C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Marc Rubin | director, officer: Executive Chairman | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
Dane Hallberg | officer: See Remarks | 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire PRNewswire • 12-21-2021
By GuruFocus Research • 06-24-2023
By PRNewswire PRNewswire • 02-02-2022
By PRNewswire PRNewswire • 02-01-2021
By GuruFocusNews GuruFocusNews • 07-10-2022
By PRNewswire PRNewswire • 11-05-2021
By PRNewswire PRNewswire • 08-16-2022
By GuruFocusNews GuruFocusNews • 06-10-2022
By PRNewswire PRNewswire • 10-25-2021
By PRNewswire PRNewswire • 07-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.